SEC Tracker
Get the app

Estrella Immunopharma ESLA

Estrella Immunopharma Q2 FY23: net loss $1.0M; diluted EPS −$0.03

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Estrella Immunopharma reported for Q2 FY23, the quarter ended Dec 31, 2023, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$1.0MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Diluted EPS−$0.03No year-earlier figure tagged10-Q income statement, on EDGAR
  3. Cash and cash equivalents$9.0MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  4. Cash from operations−$11.3MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Estrella Immunopharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Fibrogen FGEN public float $21M, Jun 30, 2025
  2. Armata Pharmaceuticals ARMP public float $21M, Jun 30, 2025
  3. Imunon IMNN public float $21M, Jun 30, 2025
  4. Lunai Bioworks LNAI public float $21M, Dec 31, 2025
  5. Dare Bioscience DARE public float $21M, Jun 30, 2025